RedHill Biopharma is a biopharmaceutical company that focuses on commercialization and development of proprietary drugs for gastrointestinal (GI) diseases. The ongoing development programs of Co.'s therapeutic candidates, most in late-stage clinical development, include: RHB-204, which is for the treatment of mycobacterium avium complex disease; RHB-104, which is an investigational drug intended to treat Crohn's disease; RHB-102 (Bekinda®), which is an investigational once-daily bi-modal extended-release oral formulation of ondansetron; and RHB-106, which is an investigational tablet intended for the preparation and cleansing of the GI tract prior to the performance of abdominal procedures. We show 1 historical shares outstanding datapoints in our RDHL shares outstanding history coverage, used to compute RDHL market cap on those dates.
Understanding the changing numbers of shares outstanding, the changing
share price, and the resulting changing RDHL market cap history over the course of time is important for investors
interested in comparing RDHL's market cap history versus its peers.
Many "beginner" or "novice" investors will look at one stock trading at a price of $10 per share and another trading at
a price of $20 per share and think the latter company is worth twice as much. Of course, that is a completely meaningless comparison without also knowing how many shares outstanding there are for each of the two companies,
and then calculating their respective market caps. Comparing the share price of RDHL versus a peer is one thing; comparing
RDHL market cap versus a peer is a completely different story.
Furthermore, via fluctuation both in per-share price and in the number of shares outstanding (via issuance of new shares over time, the repurchase of existing shares),
the market cap for a company like RDHL can fluctuate over the course of history.
With this page we aim to empower investors researching RDHL by allowing them to research the RDHL market cap history. |
Free RDHL Email Alerts:
Video: The Importance of Market Cap
